Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

NCT05170503 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Esophagogastric Junction Adenocarcinoma

Interventions

DRUG: Sintilimab

Sponsor

Sun Yat-sen University